The Corporation focused on the biology of healing announced that Health Canada has granted priority review status for the New Drug Submission (NDS) the company plans to file for its plasminogen replacement therapy Ryplazim™ for the treatment of patients with plasminogen deficiency. This is another priority review status for Ryplazim™, thus showing further validation by a regulatory authority of the potential value of this life-changing drug in the treatment of plasminogen deficien
